NIH to Evaluate New Data on Breast Cancer Screening in Younger Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 11
Volume 5
Issue 11

BETHESDA, Md-NIH plans a consensus development conference to assess the most recent data on the efficacy of mammography in screening women age 40 to 49 for breast cancer. The agency plans to convene the conference on January 21-23, 1997, on the NIH Bethesda campus.

BETHESDA, Md—NIH plans a consensus development conference to assess the most recent data on the efficacy of mammography in screening women age 40 to 49 for breast cancer. The agency plans to convene the conference on January 21-23, 1997, on the NIH Bethesda campus.

The consensus panel will consider data published since the National Cancer Institute's 1993 International Workshop on Screening for Breast Cancer. This will include a review of an unpublished meta-analysis carried out by Swedish cancer researchers.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content